Top Line: Does ultrasensitive circulating tumor DNA (ctDNA) predict who may be headed for trouble after chemoradiation for locally advanced cervical cancer?
The Study: You may or may not recall the letdown of the phase III CALLA trial that found adding durvalumab to chemoradiation for locally advanced cervical cancer did not improve PFS. In this exploratory analysis, an ultrasensitive tumor-informed assay (called NeXT Personal) was performed at baseline, after treatment, and at 3 months to detect ctDNA and circulating HPV DNA. Essentially everyone had ctDNA (98.9%) and cHPV-DNA (98.9%) at baseline. In the standard and durvalumab arms, the rates of ctDNA detection dropped to 39.8% v 35.5% post-treatment and 36.4% v 23.4% at 3 months. The rates of cHPV-DNA dropped to 78% v 88.4% post-treatment and 64.1% v 68.2% at 3 months. Detectable ctDNA was strongly correlated with an increased risk of subsequent progression. The average time between ctDNA detection and clinical progression was 5.5 months. cHPV-DNA wasn’t quite as helpful as ctDNA in predicting recurrence risk. At the 3 month post-treatment mark, the negative predictive value for ctDNA detection was 94% and the positive predictive value was 74%. In other words, those who cleared ctDNA at 3 months had <10% chance of recurrence.
TBL: Ultrasensitive tumor-informed ctDNA testing could spot residual disease months before clinical progression following definitive chemoradiation for locally advanced cervical cancer, which could guide surveillance efforts and even maintenance treatment. | Mayadev, Ann Oncol 2025
The Study: You may or may not recall the letdown of the phase III CALLA trial that found adding durvalumab to chemoradiation for locally advanced cervical cancer did not improve PFS. In this exploratory analysis, an ultrasensitive tumor-informed assay (called NeXT Personal) was performed at baseline, after treatment, and at 3 months to detect ctDNA and circulating HPV DNA. Essentially everyone had ctDNA (98.9%) and cHPV-DNA (98.9%) at baseline. In the standard and durvalumab arms, the rates of ctDNA detection dropped to 39.8% v 35.5% post-treatment and 36.4% v 23.4% at 3 months. The rates of cHPV-DNA dropped to 78% v 88.4% post-treatment and 64.1% v 68.2% at 3 months. Detectable ctDNA was strongly correlated with an increased risk of subsequent progression. The average time between ctDNA detection and clinical progression was 5.5 months. cHPV-DNA wasn’t quite as helpful as ctDNA in predicting recurrence risk. At the 3 month post-treatment mark, the negative predictive value for ctDNA detection was 94% and the positive predictive value was 74%. In other words, those who cleared ctDNA at 3 months had <10% chance of recurrence.
TBL: Ultrasensitive tumor-informed ctDNA testing could spot residual disease months before clinical progression following definitive chemoradiation for locally advanced cervical cancer, which could guide surveillance efforts and even maintenance treatment. | Mayadev, Ann Oncol 2025

